公开(公告)号：US20150297696A1

公开(公告)日：2015-10-22

申请号：US14489182

申请日：2014-09-17

申请人： OBI Pharma, Inc.

发明人： Cheng-Der Tony YU ,  Cheng-Chi Irene Wang ,  Wei-Han Lee ,  Yu-Chen Lin ,  Yu-Hsin Tom Lin ,  I-Ju Chen

IPC分类号： A61K39/00 ,  A61K47/48

摘要： The invention encompasses therapeutic compositions including Globo H-KLH conjugates and/or therapeutic antibodies as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. An effective immune response is one that reduces the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

摘要翻译： 本发明包括包括Globo H-KLH缀合物和/或治疗性抗体的治疗组合物，以及制备和使用其来治疗增殖性疾病如癌症的方法。 治疗性缀合物包括与载体连接的抗原。 特别地，治疗性缀合物包括Globo H部分和KLH部分和/或任选通过连接体连接的衍生的KLH部分亚基。 部分设想治疗组合物作为癌症疫苗，以通过免疫系统增强身体的自然保护能力，避免受损或异常细胞如癌细胞引起的危险。 有效的免疫应答是降低疾病严重性的因素，包括但不限于预防疾病，疾病发作延迟，症状严重程度降低，发病率下降和延迟死亡。

公开(公告)号：US12053514B2

公开(公告)日：2024-08-06

申请号：US14489182

申请日：2014-09-17

申请人： OBI Pharma, Inc.

发明人： Cheng-Der Tony Yu ,  Cheng-Chi Irene Wang ,  Wei-Han Lee ,  Yu-Chen Lin ,  Yu-Hsin Tom Lin ,  I-Ju Chen

IPC分类号： A61K39/00 ,  A61K47/64 ,  G01N21/64

CPC分类号： A61K39/001173 ,  A61K47/643 ,  A61K47/646 ,  G01N21/64 ,  A61K2039/55577 ,  A61K2039/6081 ,  A61K2039/627 ,  A61K2039/64

摘要： The invention encompasses therapeutic compositions including Globo H-KLH conjugates and/or therapeutic antibodies as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. An effective immune response is one that reduces the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.